Drug Guidance for Subsidy 01/04/2022 Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension The Ministry of Health’s Drug Advisory Committee has recommended: Brinzolamide 1% eye drops; ... See all × 01/04/2022 Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension The Ministry of Health’s Drug Advisory Committee has recommended: Brinzolamide 1% eye drops; and Brinzolamide/timolol 1%/0.5% eye drops in line with their registered indications for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension, in view of acceptable price proposals from the manufacturer. Subsidy status RBrinzolamide 1% and brinzolamide/timolol 1%/0.5% eye drops are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications. NRSDL subsidy does not apply to brinzolamide/brimonidine 1%/0.2% eye drops in view of unacceptable price proposal from the manufacturer.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Ophthalmic Suspension, Sterile, Brimonidine Tartrate 2 mg/mL + Brinzolamide 10 mg/mL Alexandra Hospital Changi General Hospital Khoo Teck Puat Hospital Ng Teng Fong General Hospital National University Hospital Sengkang General Hospital Singapore National Eye Centre Tan Tock Seng Hospital Woodlands Health Campus
OPHTHALMIC Select a brand starting with the letter: S SIMBRINZA EYE DROPS, SUSPENSION 10 MG/ML + 2 MG/ML [SIN15085P]